Research We Funded

Your generous support enables the ALS Association - Orange County to fund millions of dollars in research every year, in locations across the globe. From individual projects to global collaborations, we provide funding to experts in a variety of scientific focus areas critical to advancing the search for treatments and a cure for ALS.

Sampling of Grants We Have Funded During the Past 3 Years

Grant ID Project Title Applicant Award Start Date Award End Date Award Amount Primary Organization Program Name
21-SI-569Maintain the SOD1 breeding colony in 2020Torvund-Jensen, Julie02/01/202001/31/2021102600.00Taconic Biosciences, Inc.Strategic Initiative
21-MALS-568Eye Gaze Controlled Neck Brace for ALS Patients with Head DropAgrawal, Sunil02/01/202005/31/2023200000.00The Trustees of Columbia University in the City of New YorkManaging ALS - MALS
20-SI-543Natural History Pilot Project-NUAjroud-Driss, Senda01/01/202006/30/202025659.00Northwestern University - Evanston CampusStrategic Initiative
22-PDF-609An Integrated Genome-Based Approach to Individualised Treatment in ALS and FTDAl Khleifat, Ahmad01/31/202209/30/2023150000.00King's College London, Institute of PsychiatryMilton Safenowitz Postdoctoral Fellowship Program
23-SI-6212022 Holloway Postdoc Fellowship (AFTD/ALS Association)Anderson, Eric07/01/202206/30/202460000.00University of PittsburghStrategic Initiative
20-MALS-555Development and usability of a neuromuscular wearable system to enable reliable caregiver alerts and communication for people with ALSAng, Dexter01/31/202007/31/2022200000.00Pison Technology IncManaging ALS - MALS
20-SI-561Natural History Pilot Project-Henry Ford HealthArcila Londono, Ximena01/01/202009/30/202025659.00Henry Ford Health SystemStrategic Initiative
23-CSDA-6182022 Clinician Scientist Development AwardArnold, Frederick07/01/202206/30/2025168000.00The Regents of the University of California (Irvine)Clinician Scientist Development Award
21-DDC-565Targeting soITNF-dependent inflammation in ALS with XPro1595Barnum, Christopher02/01/202010/31/2022500000.00INmuneBio Inc.The Lawrence and Isabel Barnett Drug Development Award
20-DDC-548Targeting immune-checkpoint pathways: a novel therapeutic approach in ALSBaruch, Kuti01/31/202007/31/2022499413ImmunoBrain Checkpoint, Inc.The Lawrence and Isabel Barnett Drug Development Award
23-SI-622ALSUntangledBedlack, Richard07/01/202206/30/202566614.00Duke UniversityStrategic Initiative
20-SI-563Renewal for 17-CPT-374, The Effects of RNS60 on ALS biomarkersBeghi, Ettore01/01/202006/30/2021283622.00Istituto di Ricerche Farmacologiche Mario Negri (Mario Negri Institute for Pharmacological Research)Strategic Initiative
20-IIA-530Using peripheral macrophages (PM) as a target for ALSBoillee, Severine12/01/201903/31/2023240000Paris Brain Institute (Institut du Cerveau - ICM), CNRS, Inria, Inserm, AP-HP, Sorbonne UniversitéInvestigator-Initiated Multi-year Award
20-SI-545Neurofilament levels in Cytokinetics Vitality Phase III Longitudinal Plasma SamplesBowser, Robert01/31/202005/31/2022154000.00Iron Horse Diagnostics, Inc.Strategic Initiative
22-SI-599The Answer ALS Research Data PortalBoyce, Danielle09/01/202108/31/2023620702.00Johns Hopkins University School of MedicineStrategic Initiative
22-CRTF-595Activity and Regulation of ALS Causing Variants of Kinesin KIF5ABrent , Jonathan07/01/202106/30/2023105000.00Northwestern Memorial HospitalClinical Research Training Fellow
20-SI-562Trial of Dual Function, Gene Silencing-Replacement Therapy in Canine SOD1E40k/E40K ALSBrown, Robert01/31/202006/30/2023420000.00University of Massachusetts Chan Medical SchoolStrategic Initiative
21-IIA-571Determining the Effects of Hexanucleotide Repeat Expansion on RNA Localization and Local TranslationBurguete, Alondra03/01/202011/30/2023300000The Trustees of Columbia University in the City of New YorkInvestigator-Initiated Multi-year Award
22-SI-612Development of skin biomarker for early diagnosis of ALSChen, Shu12/01/202111/30/202260000.00University of Alabama at BirminghamStrategic Initiative
21-DDC-574Copper-ATSM and follistatin: A nerve-muscle combination therapy strategyCrouch, Peter04/01/202006/30/2022495176University of Melbourne (Melbourne University)The Lawrence and Isabel Barnett Drug Development Award
20-SI-544Accelerating the Path to Effective Treatments for ALS-Platform TrialCudkowicz, Merit01/01/202012/31/20223000000The General Hospital Corporation doing business as Massachusetts General HospitalStrategic Initiative
20-SI-539The ALS Association Clinical Trial Support Program-MGHCudkowicz, Merit01/01/202012/31/2022387658The General Hospital Corporation doing business as Massachusetts General HospitalStrategic Initiative
22-DDC-613GLP Studies on Antisense Oligonucleotide TherapiesElbaum, Daniel01/31/202201/30/2024500000.00QurAlis CorporationThe Lawrence and Isabel Barnett Drug Development Award
22-SI-602ALS Drug Rescue using a Novel Machine-Learning Based Subgroup Analysis ToolEnnist, David11/01/202101/31/2022100000.00Origent Data Sciences, Inc.Strategic Initiative
20-IIA-540Identification of Novel Targets that Regulate Stress Granules and Rescue Neurodegeneration in ALSFinkbeiner, Steve01/01/202006/30/2023300000Gladstone InstitutesInvestigator-Initiated Multi-year Award
22-CTA-610RAPA-501 Hybrid TREG/Th2 Cell Therapy of ALSFowler, Daniel01/01/202212/31/20231000000.00Rapa Therapeutics, LLCClinical Trial Awards
21-CRTF-577Feasibility and Patient/Caregiver Satisfaction of Telemedicine Visits for ALS ManagementGhasemia , Mehdi07/01/202006/30/2022105000.00Massachusetts General Hospital (The General Hospital Corporation), Boston, MAClinical Research Training Fellow
23-DDC-625TRPML1 small molecule agonists for the treatment of ALSGill, Martin10/01/202209/30/2024450272.00Libra Therapeutics, Inc.The Lawrence and Isabel Barnett Drug Development Award
22-PDF-592Molecular mechanisms influencing cognitive impairment in C9orf72 ALS/FTDGittings, Lauren07/01/202106/30/2023150000.00Dignity Health dba St. Joseph's Hospital & Medical Center, Phoenix, AZMilton Safenowitz Postdoctoral Fellowship Program
20-IIA-532ALS Gene and Environment InteractionsGoutman, Stephen12/01/201911/30/2022298676The Regents of the University of MichiganInvestigator-Initiated Multi-year Award
20-MALS-549Maximizing Social Connection in Persons with Speech Impairment Due to ALSGreen, Jordan01/31/202007/31/2022197087Massachusetts General Hospital-Institute of Health ProfessionsManaging ALS - MALS
20-SI-542Natural History Pilot Project-VCUGwathmey, Kelly01/01/202003/31/202125659.00Virginia Commonwealth UniversityStrategic Initiative
21-SI-570Natural History Pilot Project- St. Louis UniversityHayat, Ghazala02/01/202009/30/202025659.00Saint Louis UniversityStrategic Initiative
23-SGP-626Establishing an African ALS-research network to transform the ALS landscapeHeckmann, Jeannine10/01/202209/30/202350000.00University of Cape TownSeed Grants Program
21-SI-566Natural History Pilot Project- Temple UniversityHeiman-Patterson, Terry02/01/202012/31/202025659Temple UniversityStrategic Initiative
20-IIA-524Microbiome in Progression of ALSHertzberg, Vicki11/01/201902/28/2024299985.00Emory UniversityInvestigator-Initiated Multi-year Award
22-DDC-597Novel Protein Folding Gene Therapy for ALSHishiya, Akinori10/01/202109/30/2023500000.00Sola BiosciencesThe Lawrence and Isabel Barnett Drug Development Award
20-MALS-553Enabling independent home use of an intracortical brain-computer interface for control of multiple communication devicesHochberg, Leigh01/31/202006/29/2023200000.00Brown UniversityManaging ALS - MALS
21-SI-580Prognostic Value of miRNAs in biofluids from ALS patientsHornstein, Eran10/01/202005/31/202250000.00Weizmann Institute of ScienceStrategic Initiative
22-CTA-614Repurposing Enoxacin therapy for patients with ALSHornstein, Eran01/01/202212/31/2023750000.00Weizmann Institute of ScienceClinical Trial Awards
22-SI-603Neurofilament as a Fluid Biomarker of Neurodegeneration in f-FTD ProjectHorton, Wesley11/01/202110/31/2023140000.00Foundation for the National Institutes of Health, IncStrategic Initiative
20-IIA-529Countering the aggregation of TDP-43, FUS, DRPs, and Martin 3 with engineered protein disaggregasesJackrel, Meredith11/01/201912/31/2023300000.00Washington University in St.LouisInvestigator-Initiated Multi-year Award
22-PDF-604Smartphone-based Digital Phenotyping in People with ALSJohnson, Stephen10/01/202109/30/202275000.00Massachusetts General Hospital (Mass General)Milton Safenowitz Postdoctoral Fellowship Program
22-PDF-601Dysfunction and degeneration of corticospinal tract neurons in ALS mouse modelsKalambogias, John10/01/202109/30/2023150000.00The Trustees of Columbia University in the City of New YorkMilton Safenowitz Postdoctoral Fellowship Program
21-SI-584Sleep, stress and Caregiving: Young Caregivers in ALSKavanaugh, Melinda12/01/202008/31/202228624.00University of Wisconsin-MilwaukeeStrategic Initiative
21-SI-576Brainstorm BCT-002 US Biomarker ResearchKern, Ralph09/01/202005/31/2022500000.00Brainstorm Cell Therapeutics, IncStrategic Initiative
23-SEA-6202022 Sheila Essey Award for ALS ResearchKiernan, Matthew07/01/202206/30/202350000.00Neuroscience Research AustraliaSheila Essey Award
22-SI-600The role of circRNAs in the pathogenesis of motor neuron degenerationKing, Peter H.09/01/202108/31/2023100000.00University of Alabama at BirminghamStrategic Initiative
21-PDF-582The mechanism by which loss of stathmin-2 induces neurodegeneration in ALSKoike, Yuka01/31/202101/30/2023150000.00Mayo Clinic JacksonvilleMilton Safenowitz Postdoctoral Fellowship Program
21-CSDA-578Examining the role of ATM in selective vulnerability in ALSKreple , Collin07/01/202007/01/2022168000.00Washington University in St.LouisClinician Scientist Development Award
21-MALS-572A Mindful Community for People with ALS and their Primary CaregiversLanger, Ellen03/01/202004/30/2023200000.00President & Fellows of Harvard CollegeManaging ALS - MALS
20-DDC-533Validation of Efficacy for an Inhibitor of TDP-43 Pathology in the DNLS Mouse Model of ALSLarsen, Glenn12/01/201911/30/2020194343Aquinnah Pharmaceuticals IncThe Lawrence and Isabel Barnett Drug Development Award
22-DDC-606Preclinical evaluation of bemcentinib as a novel therapeutic for ALSLee, Virginia01/15/202201/14/2024500000.00Perelman School of Medicine, University of PennsylvaniaThe Lawrence and Isabel Barnett Drug Development Award
22-PDF-588Validating SYF2 suppression as a therapeutic strategy for diverse forms of ALSLi, Yichen02/01/202101/31/2023150000.00University of Southern California (USC)Milton Safenowitz Postdoctoral Fellowship Program
20-SI-537Natural History Pilot Project-NEMOLunetta, Christian01/01/202009/30/202025659.00Centro Clinico NEMOStrategic Initiative
21-PDF-564Unravelling shared molecular mechanisms in familial Amyotrophic Lateral SclerosisMarques, Christine02/01/202001/31/2022100000.00The General Hospital Corporation doing business as Massachusetts General HospitalMilton Safenowitz Postdoctoral Fellowship Program
21-PDF-587Longitudinal cognition and behavior in presymptomatic ALS gene mutation carriersMcHutchison, Caroline01/31/202101/30/2023148849.00University of EdinburghMilton Safenowitz Postdoctoral Fellowship Program
21-SI-579Establishing the Natural History of Upper Motor Neurondominant ALS and PLSMitsumoto, Hiroshi08/01/202007/31/2023220000.00The Trustees of Columbia University in the City of New YorkStrategic Initiative
20-IIA-531Identifying NK Cells as a Therapeutic Targets in ALSMurdock, Benjamin12/01/201902/28/2023300000The Regents of the University of MichiganInvestigator-Initiated Multi-year Award
20-IIA-546Discovery of novel phenotypes of amyotrophic lateral sclerosis based on neurophysiological measures of network dysfunction for patient stratification in clinical trialsNasseroleslami, Bahman01/01/202006/30/2023300000The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth near DublinInvestigator-Initiated Multi-year Award
20-SI-559HERV-K (HML-2) Suppression using Antiretroviral Therapy in Volunteers with ALSNath, Avindra01/01/202002/29/2024348556National Institute of Neurological Disorders and Stroke, NIH NINDSStrategic Initiative
20-SI-547Natural History Pilot Project-ProvidenceOlney, Nicholas01/01/202009/30/202025659.00Providence Health and Services- Oregon dba ProvidenceStrategic Initiative
22-PDF-605Pathomechanisms of ALS caused by SPTLC1 mutationsPant, Devesh01/15/202201/14/2024150000.00Emory UniversityMilton Safenowitz Postdoctoral Fellowship Program
21-PDF-585Pathogenic mechanisms of ALS caused by KIF5A mutationsParameswaran, Janani01/31/202101/30/2023150000.00Emory UniversityMilton Safenowitz Postdoctoral Fellowship Program
585-ClosedPathogenic mechanisms of ALS caused by KIF5A mutationsParameswaran, Janani01/31/202101/30/20230.00Emory UniversityMilton Safenowitz Postdoctoral Fellowship Program
20-IIA-525Harnessing the heterogenity of neuroinflammatory responses to tackle neurodegeneration in Amyotrophic Lateral SclerosisPeviani, Marco12/01/201911/30/2022276100Università di PaviaInvestigator-Initiated Multi-year Award
20-DDC-550Preclinical evaluations of a novel small molecule Toll-Like 2 receptor (TLR2) antagonist as a putative ALS therapeuticPrice, Diana01/31/202004/30/2022500000.00Neuropore Therapies, IncThe Lawrence and Isabel Barnett Drug Development Award
23-PDF-623Applying the human disaggregase, HtrA1, to counter Amyotrophic Lateral SclerosisPURI, ANURADHIKA08/01/202207/31/2024150000.00Washington University in St.LouisMilton Safenowitz Postdoctoral Fellowship Program
20-SI-536TDP43 Biomarker InitiativeRaisinghani, Manish01/01/202004/30/2021350000Target ALS FoundationStrategic Initiative
20-DDC-551Pre-clinical development of a Live Biotherapeutic Product used in the treatment of ALSReyes, Christopher01/31/202001/30/2022500000Bloom Science CoThe Lawrence and Isabel Barnett Drug Development Award
22-CTA-615Target NMJ to maintain motor functions in ALSRobitaille, Richard01/30/202201/29/2025996938.06Université de MontréalClinical Trial Awards
21-SI-581Development of ALS genetic testing guidelinesRoggenbuck, Jennifer12/01/202006/30/2022149188.00The Ohio State UniversityStrategic Initiative
20-PDF-527C9ORF72: Endobody vaccine for the treatment of C9 ALS/FTDRomano, Lisa11/01/201910/31/2021100000.00University of FloridaMilton Safenowitz Postdoctoral Fellowship Program
22-DDC-608ASO mediated knockdown of CHMP7 as a novel therapeutic strategy for ALS/FTDRothstein, Jeffrey01/01/202212/31/2023494444.00Johns Hopkins University School of MedicineThe Lawrence and Isabel Barnett Drug Development Award
21-SEA-575Sheila Essey Award 2020Rouleau , Guy05/21/202005/20/202150000.00Montreal Neurological Hospital and InstituteSheila Essey Award
22-CSDA-594Lysosomal Protease Dysfunction in Amyotrophic Lateral SclerosisSampognaro, Paul07/01/202106/30/2024168000.00The Regents of the University of California, San FranciscoClinician Scientist Development Award
21-SI-573Renewal for 16-LGCA-311, Integrated genomics in clinical AKS: PBMC library generationSareen, Dhruv03/01/202003/31/202139990Cedars-Sinai Medical CenterStrategic Initiative
22-DDC-607Antagonism of RAGE/DIAPH1 and Therapies for Amyotrophic Lateral SclerosisSchmidt, Ann Marie01/01/202212/31/2023500000.00New York University Grossman School of MedicineThe Lawrence and Isabel Barnett Drug Development Award
22-PDF-590Ten finger typing using an intra-cortical implant for fast communication in ALSShah, Nishal02/01/202101/31/2023150000.00The Board of Trustees of the Leland Stanford Junior UniversityMilton Safenowitz Postdoctoral Fellowship Program
20-SI-552The ALS Association Clinical Trial Support Program-BNIShefner, Jeremy01/01/202012/31/2022264885Dignity Health dba St. Joseph's Hospital & Medical Center, Phoenix, AZStrategic Initiative
23-CRTF-6192022 Clinical Research Training ScholarshipShellikeri, Sanjana07/01/202206/30/2024105000.00Perelman School of Medicine, University of PennsylvaniaClinical Research Training Fellow
20-SI-535ALS Focus PlatformSherman, Alexander01/01/202006/30/2021304669.00The General Hospital Corporation doing business as Massachusetts General HospitalStrategic Initiative
20-SI-541Natural History Pilot Project-MGHSherman, Alexander01/01/202006/30/202044240The General Hospital Corporation doing business as Massachusetts General HospitalStrategic Initiative
21-SI-567The Pooled Resource Open Access ALS Clinical Trials (Pro-Act) DatabaseSherman, Alexander02/01/202001/31/20231262129The General Hospital Corporation doing business as Massachusetts General HospitalStrategic Initiative
22-SI-596ALS FOCUS Program, Surveys, Maintenance, and SupportSherman, Alexander07/01/202108/31/2023263050.00Massachusetts General Hospital (Mass General)Strategic Initiative
20-SI-557Expanded Access to the FUS-ASO, Jacifusen for the Treatment of Mutant FUS-Associated ALSShneider, Neil01/01/202012/31/2022650000.00The Trustees of Columbia University in the City of New YorkStrategic Initiative
20-IIA-534Antagonizing neurotoxic phase transitions of TDP-43 and FUS with small RNA therapeuticsShorter, James12/01/201902/28/2023300000The Trustees of the University of PennsylvaniaInvestigator-Initiated Multi-year Award
20-MALS-554Respiratory Health Management in Amytrophic Lateral Sclerosis through Telemonitoring and Nurse Health CoachingSimmons, Zachary01/31/202007/31/2023197302.00The Pennsylvania State UniversityManaging ALS - MALS
22-CTA-611Acute adenosine receptor antagonism to promote breathing plasticity in ALSSmith, Barbara01/01/202212/31/2024880826.00University of FloridaClinical Trial Awards
22-PDF-591Family-based self-compassion intervention for reducing self-stigma in ALSSommers-Spijkerman, Marion07/01/202106/30/2023150000.00University Medical Center UtrechtMilton Safenowitz Postdoctoral Fellowship Program
23-SI-616Establishing causative roles for SARM1 coding & expression level variants in ALSSreedharan, Jemeen03/01/202208/31/2024400000.00King's College London, Institute of PsychiatryStrategic Initiative
21-SI-586Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for ALSSTAFF, NATHAN01/31/202112/31/2023252000.00Mayo Clinic RochesterStrategic Initiative
22-DDC-598Development of a matrix metalloproteinase inhibitor for the treatment of ALSSucholeiki, Irving10/01/202107/31/2023500000.00Aquilus Pharmaceuticals, Inc.The Lawrence and Isabel Barnett Drug Development Award
22-SI-589Maintain the SOD1 breeding colony in 2021Torvund-Jensen, Julie02/01/202101/31/2022145800.00Taconic Biosciences, Inc.Strategic Initiative
23-SI-617Maintain the SOD1 breeding colony in 2022Torvund-Jensen, Julie02/01/202201/31/2023343410.00Taconic Biosciences, Inc.Strategic Initiative
20-IIA-526ALS Patient Progression Tracking Mobile App vs Clinical Data CollectionTyler, Chris12/01/201911/30/2022300000ALS Never Surrender FoundationInvestigator-Initiated Multi-year Award
21-PDF-583Determining mechanisms of TDP-43 liquid-liquid phase separation and aggregationVazquez-Sanchez, Sonia01/31/202101/30/2023150000.00Ludwig Instituite for Cancer ResearchMilton Safenowitz Postdoctoral Fellowship Program
22-SEA-593Sheila Essey Award 2021Veldink, Jan04/21/202104/20/202250000.00University Medical Center UtrechtSheila Essey Award
20-SI-558Natural History Pilot Project- University of MinnesotaWALK, DAVID01/01/202010/31/202025659.00Regents of the University of Minnesota - Twin CitiesStrategic Initiative
20-MALS-538Eye gaze-based technology using Apple TrueDepth camera to enable communication for ALS patientsWang, Fusheng01/31/202007/31/2022199998State University of New York, Stony BrookManaging ALS - MALS
20-SI-560Natural History Pilot Project- University of FloridaWymer, James01/01/202006/30/202025659.00University of FloridaStrategic Initiative
20-IIP-556Developing Chemically Induced Senescence to Model ALS Pathogenesis Using iPSCsZhang, Su Chun01/31/202004/30/202150000.00University of Wisconsin-Madison (Board of Regents University of Wisconsin System)Investigator-Initiated Starter Award